• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

减轻长期抗精神病药物治疗期间的副作用负担:“换药”的作用。

Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications.

作者信息

Weiden Peter J, Buckley Peter F

机构信息

Department of Psychiatry, State University of New York (SUNY) Downstate Medical Center, Brooklyn, NY, USA.

出版信息

J Clin Psychiatry. 2007;68 Suppl 6:14-23.

PMID:17650055
Abstract

One of the great challenges of long-term treatment of schizophrenia and related disorders is minimizing the medical or psychological burden from persistent side effects. Because of the differences in side effect profiles between the newer and older antipsychotic medications, and distinct differences among the newer agents themselves, the spectrum of side effects associated with antipsychotic therapy has changed tremendously. The authors review changing from one antipsychotic to another ("switching") as a potential treatment strategy for reducing the overall side effect burden of antipsychotic therapy. This review identifies 6 steps to the evaluation of switching antipsychotics because of side effects: (1) Establish a causal attribution that the clinical problem is an adverse effect of the antipsychotic medication; (2) Understand the course of the side effect, especially regarding present and future risks for the individual patient receiving the antipsychotic treatment; (3) Understand the potential risks and benefits of other side effect interventions that do not require switching the antipsychotic; (4) Be aware of the side effect profiles of other possible antipsychotics, with an understanding of the potential effectiveness of changing (switching) to another antipsychotic for this side effect; (5) Calculate the side effect risks of switching antipsychotics; (6) Calculate the efficacy risks of switching antipsychotics. The authors explain how to evaluate the specific side effect in the context of the current medication and the overall management of the patient.

摘要

精神分裂症及相关疾病长期治疗面临的重大挑战之一,是将持续副作用带来的医学或心理负担降至最低。由于新型和老式抗精神病药物在副作用方面存在差异,且新型药物本身也有明显不同,抗精神病治疗相关的副作用谱已发生了巨大变化。作者回顾了从一种抗精神病药物换用另一种药物(“换药”)作为减轻抗精神病治疗总体副作用负担的潜在治疗策略。本综述确定了因副作用而评估抗精神病药物换药的6个步骤:(1)确定临床问题是抗精神病药物的不良反应这一因果关系;(2)了解副作用的病程,特别是对于接受抗精神病治疗的个体患者当前和未来的风险;(3)了解其他无需更换抗精神病药物的副作用干预措施的潜在风险和益处;(4)知晓其他可能的抗精神病药物的副作用谱,理解针对此副作用换用另一种抗精神病药物的潜在有效性;(5)计算更换抗精神病药物的副作用风险;(6)计算更换抗精神病药物的疗效风险。作者解释了如何在当前用药及患者整体管理的背景下评估特定副作用。

相似文献

1
Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications.减轻长期抗精神病药物治疗期间的副作用负担:“换药”的作用。
J Clin Psychiatry. 2007;68 Suppl 6:14-23.
2
Strategies for dosing and switching antipsychotics for optimal clinical management.用于优化临床管理的抗精神病药物给药和换药策略。
J Clin Psychiatry. 2008;69 Suppl 1:4-17.
3
[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].[法国13家精神病医院抗精神病药物的处方模式]
Encephale. 2009 Apr;35(2):129-38. doi: 10.1016/j.encep.2008.03.007. Epub 2008 Jul 7.
4
Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia.更换抗精神病药物作为治疗抗精神病药物所致体重增加和血脂异常的一种策略。
J Clin Psychiatry. 2007;68 Suppl 4:34-9.
5
Switching antipsychotics: an updated review with a focus on quetiapine.更换抗精神病药物:以喹硫平为重点的最新综述
J Psychopharmacol. 2006 Jan;20(1):104-18. doi: 10.1177/0269881105056668. Epub 2005 Oct 4.
6
Abstinence, anticipation, reduction, and treatment (AART): a stepwise approach to the management of atypical antipsychotic side effects.禁欲、预期、减少和治疗(AART):非典型抗精神病药物副作用管理的逐步方法。
Essent Psychopharmacol. 2006;7(1):1-14.
7
Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents.抗精神病药物的受体结合特征:不同药物间转换时的临床策略
J Clin Psychiatry. 2007;68 Suppl 6:5-9.
8
Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.停用和更换抗精神病药物:解读精神分裂症患者抗精神病药物治疗的临床抗精神病药物干预有效性试验(CATIE)
J Clin Psychiatry. 2007;68 Suppl 1:12-9.
9
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.抗精神病药物联合治疗的利弊:2008年3月于法国尼斯召开的欧洲神经精神药理学会(ECNP)共识会议
Eur Neuropsychopharmacol. 2009 Jul;19(7):520-32. doi: 10.1016/j.euroneuro.2009.04.003. Epub 2009 May 2.
10
Sexual side effects associated with conventional and atypical antipsychotics.与传统及非典型抗精神病药物相关的性功能副作用。
Psychopharmacol Bull. 2001 Summer;35(3):89-108.

引用本文的文献

1
Brexpiprazole has a low risk of dopamine D receptor sensitization and inhibits rebound phenomena related to D and serotonin 5-HT receptors in rats.布雷哌唑具有较低的多巴胺 D 受体致敏风险,并能抑制大鼠中与 D 和 5-羟色胺 5-HT 受体相关的反弹现象。
Neuropsychopharmacol Rep. 2019 Dec;39(4):279-288. doi: 10.1002/npr2.12076. Epub 2019 Sep 5.
2
Aripiprazole: from pharmacological profile to clinical use.阿立哌唑:从药理学特性到临床应用
Neuropsychiatr Dis Treat. 2015 Oct 13;11:2635-47. doi: 10.2147/NDT.S88117. eCollection 2015.
3
Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders.
基于组学的生物标志物:代谢组学在神经精神疾病中的应用
Int J Neuropsychopharmacol. 2015 Oct 9;19(3):pyv096. doi: 10.1093/ijnp/pyv096.
4
[Adherence to psychopharmacological treatment: Psychotherapeutic strategies to enhance adherence].[坚持心理药物治疗:提高依从性的心理治疗策略]
Nervenarzt. 2015 May;86(5):637-46; quiz 647-8. doi: 10.1007/s00115-015-4275-z.
5
Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study.从奥氮平转换为阿立哌唑对伴有代谢综合征的精神分裂症患者代谢谱的影响:一项双盲、随机、开放标签研究。
Neuropsychiatr Dis Treat. 2015 Mar 13;11:685-93. doi: 10.2147/NDT.S80925. eCollection 2015.
6
Consumers' questions about antipsychotic medication: revealing safety concerns and the silent voices of young men.消费者关于抗精神病药物的问题:揭示安全担忧与年轻男性的无声之声。
Soc Psychiatry Psychiatr Epidemiol. 2015 May;50(5):725-33. doi: 10.1007/s00127-014-1005-y. Epub 2014 Dec 30.
7
[Computer-assisted treatment pathway for schizophrenia. Development and initial experiences].[精神分裂症的计算机辅助治疗路径。开发与初步经验]
Nervenarzt. 2015 Jan;86(1):51-9. doi: 10.1007/s00115-013-3818-4.
8
[Long-term treatment of schizophrenia spectrum disorders: focus on pharmacotherapy].[精神分裂症谱系障碍的长期治疗:聚焦药物治疗]
Nervenarzt. 2014 Mar;85(3):363-75; quiz 376-7. doi: 10.1007/s00115-013-3807-7.
9
SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects.SMARTS(与治疗相关的不良事件系统监测):开发实用的患者完成的清单,以评估抗精神病药物的副作用。
Ther Adv Psychopharmacol. 2014 Feb;4(1):15-21. doi: 10.1177/2045125313510195.
10
Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.鲁拉西酮对从其他抗精神病药物转换过来的精神分裂症或精神分裂症-情感障碍患者的有效性:一项为期6个月的开放标签延长期研究。
CNS Spectr. 2014 Aug;19(4):330-9. doi: 10.1017/S109285291300093X. Epub 2013 Dec 16.